Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 12/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17194373 | 0.83 | ADORA1 (0.48) | KDM4EMAPTP2RX3ADORA1MKNK1 | |
| SCHEMBL17194353 | 0.80 | ADORA1 (0.50) | KDM4EMAPTGAAP2RX3ADORA1 | |
| SCHEMBL17194169 | 0.77 | L3MBTL1 (0.52) | KDM4EMAPTGAAADORA1MKNK1 | |
| SCHEMBL20922384 | 0.76 | ADORA1 (0.55) | KDM4EMAPTGAAP2RX3ADORA1 | |
| SCHEMBL17194176 | 0.76 | ADORA1 (0.55) | KDM4EMAPTGAAP2RX3ADORA1 | |
| SCHEMBL17194311 | 0.76 | ADORA1 (0.55) | KDM4EMAPTGAAP2RX3ADORA1 | |
| SCHEMBL2643671 | 0.76 | MAPT (0.73) | KDM4EMAPTGAAADORA1MKNK1 | |
| SCHEMBL4510907 | 0.75 | ADORA1 (0.45) | KDM4EMAPTGAAP2RX3ADORA1 | |
| SCHEMBL17194296 | 0.74 | ADORA1 (0.53) | KDM4EMAPTGAAP2RX3ADORA1 | |
| SCHEMBL13473579 | 0.74 | P2RX3 (0.54) | P2RX3MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131890-B1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | PASTEUR INSTITUT KOREA (KR) | 2019-04-24 | — | — | EP | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
| WO-2015158908-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | KDM4E 4004/4885MAPT 2197/4885GAA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.